Sanofi is trying to assuage concerns about its Dengvaxia dengue vaccine with a label recommendation against use in individuals who have never been infected with dengue and discussions with health and regulatory authorities.
The company has faced questions about the vaccine since announcing the results of a new analysis of long-term clinical trial...







